Novo Nordisk slides while Moderna pops: Tale of two pharma stocks

Galen Weston calls Loblaw boycott 'misguided criticism', says grocer not responsible for higher prices

"Their frustration is understandable, but this kind of expectation betrays a misunderstanding of what's actually driving food prices higher in this country."This dividend stock is near 52-week highs, but still down from all-time highs, with a highly valuable P/E ratio you won't want to miss. The post 1 Magnificent Dividend Stock That’s Down 21% and Trading at a Once-in-a-Decade Valuation appeared first on The Motley Fool Canada.The Canadian dollar strengthened against its U.S.

-- Traders on Wall Street cheered on Wednesday when Federal Reserve Chair Jerome Powell signaled he didn’t see oncoming interest-rate hikes despite inflationary pressures. The celebration didn’t last long.Most Read from BloombergUS and Saudis Near Defense Pact Meant to Reshape Middle EastJerome Powell Offered Markets a Reprieve.

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Novo Nordisk raises 2024 outlook as company races to boost output of Wegovy weight-loss drugNovo Nordisk reported better-than-expected first-quarter profits on Thursday as it looks to fend off competition from rival Eli Lilly
Source: globeandmail - 🏆 5. / 92 Read more »

Novo Nordisk CEO on weight-loss drugs' 'exciting growth story'Danish pharmaceutical company Novo Nordisk (NVO) topped first-quarter profit expectations, bringing in $9.5 billion in revenue over Wall Street estimates of ...
Source: YahooFinanceCA - 🏆 47. / 63 Read more »

Novo Nordisk sales up 26% driven by GLP-1s, misses 11% on WegovyNovo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.
Source: YahooFinanceCA - 🏆 47. / 63 Read more »